Forum

Your browser does not seem to support JavaScript. As a result, your viewing experience will be diminished, and you have been placed in read-only mode.

Please download a browser that supports JavaScript, or enable it if it's disabled (i.e. NoScript).

Forum Update: Supporting Community-Led Discussion

The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.

Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:

Correct any misunderstandings
Provide guidance when questions remain unanswered after a few days
Support discussions where official clarification is needed

Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.

Thank you for being part of the conversation.

PAAB Forum Quarterly Review - Q1/2023

Blogs

1 Posts 1 Posters 842 Views 1 Watching

J Offline
J Offline
Jennifer Carroll

wrote on last edited by

#1

Happy Spring @Manufacturer and @Agency

The first quarter of 2023 has been a big one. We've launched consultation on two draft guidance documents, posted additional guidance on gating, and an advisory on formulary claims, launched the Customer Experience Index (CEI) and more. See the PAAB Forum Quarterly Review to get caught up on all the action in Q1.

Please be advised
PAAB modified business hours for 2023 will start on Monday May 1st and end on Friday October 6th.

PAAB summer business operating hours will be:
Monday to Thursday 8:30 - 5:30pm
Friday 8:30 - 1:15pm

Please note: eFiles modified hours submission end times will be:
Monday - Thursday 4:30pm
Friday 12:15pm

On behalf of the PAAB staff, have a safe and happy spring season.
1 Reply Last reply

2

The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.